Devopharma ApS: Financial statements 2023
CVR: 38968254
Source: annual report 2023, Danish Business Authority
01/01/2023 – 31/12/2023
Devopharma ApS (CVR 38968254) has filed annual accounts for 2023. In 2023, the company reported a gross profit of DKK -3,125 and a net result of DKK -3,125 compared with DKK -3,125 the year before. Equity in the 2023 report amounted to DKK 31,250. The solvency ratio was 31.3%.
- Gross Profit
- DKK -3,125
- Profit/Loss
- DKK -3,125
- Equity
- DKK 31,250
- Total Assets
- DKK 100,000
- Employees
- 0
Development
| Year | Revenue | Gross Profit | Profit/Loss | Equity | Employees |
|---|---|---|---|---|---|
| 2023 | - | -3 t. | -3 t. | 31 t. | 0 |
| 2022 | - | -3 t. | -3 t. | 34 t. | 0 |
| 2021 | - | -3 t. | -3 t. | 38 t. | 0 |
| 2020 | - | -3 t. | -3 t. | 41 t. | 0 |
| 2019 | - | -3 t. | -3 t. | 44 t. | 0 |
Fetch this data via API
Every Danish company, financial statement and ownership record — straight into your own systems or your AI assistant via MCP.
See the API documentationEvents in 2023
Devopharma ApS has published its annual report for 2022. Gross profit came to DKK -3,125, and the net result was DKK -3,125.
About Devopharma ApS
Devopharma ApS is a Danish company of the type Anpartsselskab based in Charlottenlund, founded in 2017. The company is registered under the industry Forskning og eksperimentel udvikling inden for naturvidenskab og teknik. The management consists of Henrik Nakskov and Søren Luplau-Pagh. The company's owners include JARCO HOLDING ApS, HN HOLDING 2010 ApS and Friendly Holding ApS. In 2025, the company reported a gross profit of DKK -3,125 and a net result of DKK -3,125 compared with DKK -3,125 the year before. Equity in the 2025 report amounted to DKK 25,000.